{"filing":{"accession_number":"0001193125-26-277506","cik":"0001701108","ticker":"SPRO","company_name":"Spero Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d51395d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm"},"events":[{"id":12727,"run_id":11292,"accession_number":"0001193125-26-277506","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil), the company's lead product candidate for complicated urinary tract infections and the first-and-only oral carbapenem antibiotic approved in this indication. This represents a major regulatory milestone and transition from development to commercialization, materially affecting the company's commercial prospects and future revenue potential.","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9658,"accession_number":"0001193125-26-277506","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of Utebzi (tebipenem pivoxil), Spero's lead product candidate for complicated urinary tract infections. This is a major regulatory milestone and product approval event that materially affects the company's commercial prospects and pipeline. While not a traditional earnings release, M\u0026A activity, or financial obligation, the FDA approval of a first-and-only oral carbapenem antibiotic represents a significant operational and strategic achievement that would affect a reasonable investor's assessment of the company's value and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:36.568827+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9659,"accession_number":"0001193125-26-277506","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of Utebzi (tebipenem pivoxil), Spero's first approved product, representing a major regulatory and commercial milestone. While this is a significant operational achievement for a clinical-stage biopharmaceutical company, it does not fit the specific taxonomy categories: it is not an earnings release (no financial results), not a debt/equity issuance, not M\u0026A activity, and not a traditional governance or financial event. The approval is material to investors as it marks the transition from development to commercialization and validates the company's lead program, but the event is fundamentally operational—a product regulatory milestone—rather than fitting a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:36.568827+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9658,"accession_number":"0001193125-26-277506","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of Utebzi (tebipenem pivoxil), Spero's lead product candidate for complicated urinary tract infections. This is a major regulatory milestone and product approval event that materially affects the company's commercial prospects and pipeline. While not a traditional earnings release, M\u0026A activity, or financial obligation, the FDA approval of a first-and-only oral carbapenem antibiotic represents a significant operational and strategic achievement that would affect a reasonable investor's assessment of the company's value and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:36.568827+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-22"},{"id":9659,"accession_number":"0001193125-26-277506","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of Utebzi (tebipenem pivoxil), Spero's first approved product, representing a major regulatory and commercial milestone. While this is a significant operational achievement for a clinical-stage biopharmaceutical company, it does not fit the specific taxonomy categories: it is not an earnings release (no financial results), not a debt/equity issuance, not M\u0026A activity, and not a traditional governance or financial event. The approval is material to investors as it marks the transition from development to commercialization and validates the company's lead program, but the event is fundamentally operational—a product regulatory milestone—rather than fitting a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:36.568827+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-22"}]}